QI
ECYT

QS Investors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

QS Investors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-86,420
Closed -$540K – 1497
2015
Q1 		$540K Sell
86,420
-3,900
-4% -$22.5K 0.01% 865
2014
Q4 		$569K Buy
+90,320
New +$551K 0.01% 838

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QS Investors's ECYT Position: Q2 2015 in Review

QS Investors sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2015, closing a stake of 86,420 shares — an estimated $540K sold.

QS Investors first reported a position in ECYT in Q4 2014 and held it in 2 quarters. The position peaked at $569K in Q4 2014. 98 funds tracked by Wall St. Rank hold ECYT as of Q2 2015.

  • QS Investors reported no remaining Endocyte, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • QS Investors sold 86,420 Endocyte, Inc. Common Stock shares in Q2 2015, an estimated $540K.
  • QS Investors first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 2 quarters.
  • QS Investors's Endocyte, Inc. Common Stock position peaked at $569K in Q4 2014.
  • 98 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2015.

Based on QS Investors's 13F filing for Q2 2015, filed 14 Aug 2015.